Croda is proud to announce that all its leading excipient manufacturing sites globally have now completed the audit requirements of EXCiPACT and have been successfully certified. Croda becomes the first multi-site excipient supplier to achieve global  accreditation across its production facilities. This certifies that all its leading excipient sites manufacture pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard.

This achievement reflects ten years’ worth of efforts by Croda’s Head of Global Quality Assurance,
Dr. Iain Moore, and the site teams. Iain has been heavily involved in shaping EXCiPACT and has been singled out by IPEC as a “leading light” in driving the accreditation forward. Back in 2014, Croda’s Rawcliffe Bridge site became one of the first few sites awarded the prestigious EXCiPACT Certificate. Since then, six other Croda manufacturing sites have been certified, accounting for over 90% of Croda’s excipient production.

Dave Cherry, Managing Director of Croda’s Health Care business said “This achievement brings significant value to both Croda and our customers, reducing the audit burden on both sides whilst maintaining confidence in Croda’s compliance to the demanding standards of the Pharmaceutical industry. The certificate assures our customers that Croda manufactures and distributes pharmaceutical excipients to EXCiPACT good manufacturing (GMP) standards. It is a measure of excellence in quality and an assurance for our customers that they are always in receipt of material of the highest standards.” 

For information on the Croda manufacturing sites that are now EXCiPACT certified and to view the portfolio of products offered, visit http://www.croda.com/healthcare

For information on EXCiPACT, visit www.excipact.org